Literature DB >> 27733948

Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease.

Hiroshi Oiwa1, Sho Mokuda2.   

Abstract

Entities:  

Year:  2016        PMID： 27733948      PMCID： PMC5058456          DOI： 10.5152/eurjrheum.2015.0049

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN： 2147-9720


× No keyword cloud information.
  6 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 2.  Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies.

Authors:  Wei-Xiang Qi; Feng Lin; Ai-Na He; Li-Na Tang; Zan Shen; Yang Yao
Journal:  Curr Med Res Opin       Date:  2013-06-24       Impact factor: 2.580

3.  Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.

Authors:  Vatsa Dave; Cherie Y Chiang; Jane Booth; Peter F Mount
Journal:  Am J Nephrol       Date:  2015-03-18       Impact factor: 3.754

4.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

5.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

6.  A single-dose study of denosumab in patients with various degrees of renal impairment.

Authors:  Geoffrey A Block; Henry G Bone; Liang Fang; Edward Lee; Desmond Padhi
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741
  6 in total
  5 in total

1.  Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.

Authors:  Nam-Kyong Choi; Daniel H Solomon; Theodore N Tsacogianis; Joan E Landon; Hong Ji Song; Seoyoung C Kim
Journal:  J Bone Miner Res       Date:  2017-02-07       Impact factor: 6.741

2.  Drug-physiology interaction and its influence on the QT prolongation-mechanistic modeling study.

Authors:  Barbara Wiśniowska; Sebastian Polak
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-15       Impact factor: 2.745

3.  Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.

Authors:  C Thongprayoon; P Acharya; C Acharya; J Chenbhanich; T Bathini; B Boonpheng; K Sharma; K Wijarnpreecha; P Ungprasert; M L Gonzalez Suarez; W Cheungpasitporn
Journal:  Osteoporos Int       Date:  2018-04-30       Impact factor: 4.507

4.  Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course.

Authors:  Jarred Strickling; Michael J Wilkowski
Journal:  Case Rep Nephrol Dial       Date:  2019-04-23

5.  High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.

Authors:  Koji Ishikawa; Takashi Nagai; Koki Tsuchiya; Yusuke Oshita; Takuma Kuroda; Hiroshi Ito; Soji Tani; Yusuke Dodo; Tomoaki Toyone; Katsunori Inagaki
Journal:  Clin Interv Aging       Date:  2018-10-08       Impact factor: 4.458
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.